p53 and bcl-2 expression correlates with clinical outcome in a series of node-positive breast cancer patients

Journal of Clinical Oncology

Volumn 14, Issue 5, 1996, Pages 1604-1610

  Silvestrini, R ^a   Benini, E ^a   Veneroni, S ^a   Daidone, M G ^a   Tomasic, G ^a   Squicciarini, P ^a   Salvadori, B ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; HORMONE RECEPTOR; ONCOPROTEIN; PROGESTERONE RECEPTOR; PROTEIN P53; TAMOXIFEN; THYMIDINE; TRITIUM;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LABELING INDEX; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MASTECTOMY; PARTIAL MASTECTOMY; PRIORITY JOURNAL; PROTO ONCOGENE; TREATMENT OUTCOME; TUMOR SUPPRESSOR GENE;

EID: 0029863353     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.5.1604     Document Type: Article

References (22)

1. Early Breast Cancer Trialists' Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 339:1-15, 71-85, 1992
2. Clark GM, Hilsenbeck SG, Ravdin PM, et al: Prognostic factors: Rationale and methods of analysis and integration. Breast Cancer Res Treat 32:105-112, 1994
3. Osborne CK: Receptors, in Harris JR, Hellman S, Henderson JC, et al (eds): Breast Disease. Philadelphia, PA, Lippincott, 1991, pp 301-305
4. Clark GM: Do we really need prognostic factors for breast cancer? Breast Cancer Res Treat 30:117-126, 1994
5. Stål O, Rutqvist LE, Carstensen JM, et al: S-phase fraction and survival benefit from adjuvant chemotherapy or radiotherapy of breast cancer. Br J Cancer 70:1258-1262, 1995
6. Silvestrini R: Cell kinetics: Prognostic and therapeutic implication in human tumors. Cell Proliferation 27:579-596, 1994
7. Lotem J, Sachs L: Regulation by bcl-2, c-myc, and p53 of susceptibility to induction of apoptosis by heat shock and cancer chemotherapy compounds in differentiation-competent and -defective myeloid leukemic cells. Cell Growth Diff 4:41-47, 1992
8. Lowe SW, Bodis S, McClatchey A, et al: p53 status and the efficacy of cancer therapy in vivo. Science 266:807-810, 1994
9. Silvestrini R, Veneroni S, Daidone MG, et al: The Bcl-2 protein: A prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. J Natl Cancer Inst 86:499-504, 1994
10. Cunningham JM, Ingle JN, Jung SH, et al: p53 gene expression in node-positive breast cancer: Relationship to DNA ploidy and prognosis. J Natl Cancer Inst 86:1871-1873, 1994
11. Nathan B, Gusterson B, Jadayel D, et al: Expression of bcl-2 in primary breast cancer and its correlation with tumour phenotype. Ann Oncol 5:409-414, 1994
12. Daidone MG, Silvestrini R, Luisi A, et al: Changes in biological markers after primary chemotherapy for breast cancers. Int J Cancer 61:301-305, 1995
13. Silvestrini R, Daidone MG, Mastore M, et al: Cell kinetics as a predictive factor in node-positive breast cancer treated with adjuvant hormone therapy. J Clin Oncol 11:1150-1155, 1993
14. Silvestrini R, Benini E, Daidone MG, et al: P53 as an independent prognostic marker in lymph node-negative breast cancer patients. J Natl Cancer Inst 85:965-970, 1993
15. Silvestrini R, Daidone MG, Luisi A, et al: Biologic and clinico-pathologic factors as indicators of specific relapse types in node-negative breast cancer. J Clin Oncol 13:697-704, 1995
16. 3H-thymidine labeling index as a prognostic indicator in node-positive breast cancer. J Clin Oncol 8:1321-1326, 1990
17. Marubini E, Valsecchi MG: Analysis of Survival Data From Clinical Trials and Observational Studies. Chichester, United Kingdom, Wiley, 1995
18. Oren M: The involvement of oncogenes and tumor suppressor genes in the control of apoptosis. Cancer Metastasis Rev 11:141-148, 1992
19. Hockenbery DM, Zutter M, Hickey W, et al: Bcl-2 protein is topographically restricted in tissues characterized by apoptotic cell death. Proc Natl Acad Sci USA 88:6961-6965, 1991
20. McGuire WL, Clark GM: Prognostic factors and treatment decisions in axillary-node-negative breast cancer. N Engl J Med 326:1756-1761, 1992
21. Pezzella F, Turley H, Kuzu I, et al: Bcl-2 protein in non-small-cell lung carcinoma. N Engl J Med 329:690-694, 1993
22. Leek RD, Kaklamanis L, Pezzella F. et al: Bcl-2 in normal human breast and carcinoma, association with oestrogen receptor-positive, epidermal growth factor receptor-negative tumours and in situ cancer. Br J Cancer 69:135-139, 1994